GSK, RSV
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
Nasdaq23d
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...
PMLiVE22d
GSK’s RSV vaccine Arexvy approved by EC for use in adults aged 50 to 59 years
GSK’s Arexvy has become the first respiratory syncytial virus (RSV) vaccine to be approved by the European Commission (EC) for use in adults aged 50 to 59 years who are at an increased risk of ...
Saugeen Times4d
Ask the Pharmacist – RSV vaccine
RSV is a common virus that affects the respiratory system primarily amongst infants, young children and older adults. Though ...
Yahoo Finance23d
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...
CBC.ca3d
Canada approved multiple RSV shots to ward off infections this fall — here's how to get them
Here's what Canadians need to know: Older adults now have access to two approved vaccines, called Arexvy and Abrysvo.